Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.

NCT04950712 · View on ClinicalTrials.gov ↗

Study Summary

The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe. More specifically, the study aims to evaluate patient-reported outcome and quality-of-life endpoints as well as the performance study procedures in a decentralised setting. Ultimately, this study will allow generating additional real-world evidence (RWE) on patterns of recurrences and other key parameters.

Conditions Studied

Interventions

  • PROCEDURE Blood sampling
  • PROCEDURE Anogenital lesion swab collection

Study Locations (20)

Florida

  • GSK Investigational Site — Miami
  • GSK Investigational Site — Miami
  • GSK Investigational Site — Miami
  • GSK Investigational Site — Plantation

California

  • GSK Investigational Site — Long Beach
  • GSK Investigational Site — Los Angeles
  • GSK Investigational Site — San Francisco

Texas

  • GSK Investigational Site — Austin
  • GSK Investigational Site — Fort Worth
  • GSK Investigational Site — Houston

Georgia

  • GSK Investigational Site — Marietta
  • GSK Investigational Site — Smyrna

Missouri

  • GSK Investigational Site — Kansas City
  • GSK Investigational Site — St Louis

New Jersey

  • GSK Investigational Site — Lawrenceville
  • GSK Investigational Site — Newark

Massachusetts

  • GSK Investigational Site — Boston

Ohio

  • GSK Investigational Site — Columbus

Trial Details

FieldValue
Enrollment Target 537 participants
Start Date 2021-06-09
Est. Completion 2024-03-14

Sponsor

GlaxoSmithKline

558 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04950712

The ClinicalTrials.gov registry entry for NCT04950712 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 537 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 558 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Herpes Genitalis appearing as the primary indexed condition, and to 2 interventions — of which Blood sampling is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04950712 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Florida, California, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04950712 about?

NCT04950712 is a clinical study titled "An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.". The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe. More specifically, the study aims to evaluate patient-reported outcome and quality-of-life endpoints as well a...

What is the current status of trial NCT04950712?

This trial is currently completed. The enrollment target is 537 participants. The study started on 2021-06-09. Estimated completion is 2024-03-14.

What conditions does trial NCT04950712 study?

This clinical trial studies the following conditions: Herpes Genitalis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04950712?

The interventions under investigation include: Blood sampling (PROCEDURE), Anogenital lesion swab collection (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04950712?

This trial is sponsored by GlaxoSmithKline, which has 558 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04950712 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial